Aurobindo Pharma Ltd’s consolidated net profit increased 17 percent at ₹836 crore in the third quarter ended December 31, 2020, against ₹715 crore in the corresponding quarter of the previous year. The total revenue increased 8 percent at ₹6365 crore, compared to `5895 crore in the same period last year. The formulation revenue for the quarter recorded a growth of 11.3 percent at `5,682 crore and accounted for 89.3 percent of the total revenues.
The revenue from the US witnessed a growth of 6.8 percent at ₹3171 crore, contributing 49.8 percent of the consolidated revenue, while revenue from Europe incased by 13.2 percent.
Research & Development (R&D) spend was at `390 crore and accounted for 6.1 percent of the revenues. During the quarter, the company received final approval for 13 ANDAs from USFDA, including nine injectables.